Radionuclide therapy rapresent one of the most effective approach for the treatment of cancer. The beta-emitting radionuclide Re-188 is considered a vary attractive candidate for the development of therapeutic radiopharmaceuticals. The aim of this study was to develop the mixed-ligand [188Re(N)(SNS)(PCN)] complex using the bifunctional approach, and evaluate its stability.

New "3+1" chelating system for the development of therapeutic agents lebeled with rhenium-188.

UCCELLI, Licia;PASQUALI, Micol;BOSCHI, Alessandra;GIGANTI, Melchiore;DUATTI, Adriano
2013

Abstract

Radionuclide therapy rapresent one of the most effective approach for the treatment of cancer. The beta-emitting radionuclide Re-188 is considered a vary attractive candidate for the development of therapeutic radiopharmaceuticals. The aim of this study was to develop the mixed-ligand [188Re(N)(SNS)(PCN)] complex using the bifunctional approach, and evaluate its stability.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2076012
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact